Advertisement

Topics

Memorial Sloan Kettering Cancer Center Company Profile

23:29 EDT 23rd September 2018 | BioPortfolio

The CMO’s Structure, Assets, and Goals


News Articles [2997 Associated News Articles listed on BioPortfolio]

Memorial Sloan Kettering provides roadmap for successful CAR-T cell program

An article from the Memorial Sloan Kettering Cancer Center (MSK) analyses what it identifies as the key…

Memorial Sloan Kettering CMO Steps Down Following His Failure to Disclose Financial Ties to the I...

Days after a report by The New York Times and ProPublica revealed José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, failed to disclose his vast financial ties to various ...

Phase III Trial Show That the Combo of Ipilimumab and Nivolumab Increases Overall Survival in People with Kidney Cancer

NewsTreating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus...

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 30032018] Prices from USD $350

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Part...

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 23042018] Prices from USD $350

Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Memorial Sloan Kettering Cancer Center Mergers Acquisitions MA, Part...

Resignation by Memorial Sloan Kettering’s Baselga should start bigger COI conversation, expert says

Memorial Sloan Kettering Chief Medical Officer Jose Baselga resigned Thursday following publication of a New York Times-ProPublica investigation of his financial relationships with drugmakers.

Fate expands off-the-shelf CAR T-cell drug partnership with cancer center

Memorial Sloan Kettering Cancer Center granted Fate Therapeutics exclusive rights to additional intellectual property coverin -More- 

BIO Communications Responds to Misleading Op-Ed about Medicaid Drug Costs

This week, Dr. Peter Bach of Memorial Sloan-Kettering Cancer Center authored an op-ed about the ...

PubMed Articles [6643 Associated PubMed Articles listed on BioPortfolio]

Multiparametric magnetic resonance imaging versus Partin tables and the Memorial Sloan-Kettering cancer center nomogram in risk stratification of patients with prostate cancer referred to external beam radiation therapy.

To evaluate the agreement between multiparametric Magnetic Resonance Imaging (mpMRI), Partin tables (PT) and the Memorial Sloan Kettering Cancer Center nomogram (MSKCCn) in assessing risk category in ...

Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Products at Memorial Sloan Kettering Cancer Center.

Two commercial Chimeric Antigen Receptor (CAR) T cell therapies for CD19 expressing B cell malignancies, Kymriah and Yescarta, have recently been approved by the FDA. The administration of CAR T cells...

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Purpose Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids ...

Has the Age of Cytoreductive Nephrectomy come to an end?

The CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) trial was a prospective, multicentre, open-label, phase 3 trial that randomly assigned patients with Memorial Sloan Ketteri...

Ameloblastomas of the mandible and maxilla.

Ameloblastoma is a histologically benign but locally aggressive tumor of the jaws. We conducted a retrospective cohort study to review the clinical, radiologic, and pathologic features of patients wit...

Clinical Trials [10508 Associated Clinical Trials listed on BioPortfolio]

Measurement of Cancer-Related Risk Perception in Smokers

The purpose of this study is to develop an accurate way of measuring people's thoughts about cancer risk. The researchers at the Queens Hospital Center, Memorial Sloan-Kettering Cancer Cen...

Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer

The purpose of this study is to collect a blood sample from patients with breast disease (cases) and from individuals without breast cancer (controls)that may be used for research purposes...

Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy

With a major liver or pancreas operation, there is a chance that one will require a transfusion of blood products (either red blood cells or plasma). This may be necessary during the oper...

A Randomized Study of Sulindac in Oral Premalignant Lesions

The purpose of this study is to see if a drug called sulindac can prevent the development of changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia) or...

Older Breast Cancer Patients: Risk for Cognitive Decline

The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore which domains are most affected, measure associations between cog...

Companies [2837 Associated Companies listed on BioPortfolio]

Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center's tradition of care began more than 100 years ago. In 1884, the cornerstone of the New York Cancer Hospital -- what was later to become Memorial Hospital for Can...

The Society of Memorial Sloan-Kettering Cancer Center

Memorial Sloan Kettering Cancer Center

The CMO’s Structure, Assets, and Goals

Optimer Pharmaceuticals

Optimer's core competence includes the development of innovative drugs for treating diseases that currently have no satisfactory therapy. These include antibiotics for drug-resistant bacterial infecti...

Mojave Therapeutics Incorporated

Mojave Therapeutics is building a new class of biopharmaceuticals that primes the immune system to fight cancer and viral diseases. Mojave’s core technologies, developed by leading researchers at Me...

More Information about "Memorial Sloan Kettering Cancer Center" on BioPortfolio

We have published hundreds of Memorial Sloan Kettering Cancer Center news stories on BioPortfolio along with dozens of Memorial Sloan Kettering Cancer Center Clinical Trials and PubMed Articles about Memorial Sloan Kettering Cancer Center for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Memorial Sloan Kettering Cancer Center Companies in our database. You can also find out about relevant Memorial Sloan Kettering Cancer Center Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record